1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Drugs In Development, 2022, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 23, 28, 50, 4, 203, 51 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 42 and 1 molecules, respectively.
Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Multiple Sclerosis - Overview
- Multiple Sclerosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Multiple Sclerosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Multiple Sclerosis - Companies Involved in Therapeutics Development
- Multiple Sclerosis - Drug Profiles
- Multiple Sclerosis - Dormant Projects
- Multiple Sclerosis - Discontinued Products
- Multiple Sclerosis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Multiple Sclerosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Multiple Sclerosis - Dormant Projects, 2022
- Multiple Sclerosis - Discontinued Products, 2022
- Number of Products under Development for Multiple Sclerosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Pharma Plc
- AB Science SA
- Abata Therapeutics
- AbbVie Inc
- Abion Inc
- Abivax SA
- Aditxt Inc
- Aequus Pharmaceuticals Inc
- Affectis Pharmaceuticals AG
- AgoneX Biopharmaceuticals Inc
- Ahead Therapeutics SL
- Akaal Pharma Pty Ltd
- Alector Inc
- Alexion Pharmaceuticals Inc
- Alpha Cancer Technologies Inc
- Alpine Immune Sciences Inc
- Altheia Science SRL
- Amarna Therapeutics BV
- Amgen Inc
- Amylyx Pharmaceuticals Inc
- Ankar Pharma SL
- Anokion SA
- Antisense Therapeutics Ltd
- AnTolRx Inc
- Apaxen
- Aphios Corp
- Apimeds Inc
- AptaTargets SL
- Artax Biopharma Inc
- ArunA Bio Inc
- Asdera LLC
- Aslan Pharmaceuticals Ltd
- Atara Biotherapeutics Inc
- Athersys Inc
- Autobahn Therapeutics Inc
- Autoimmunity Biologic Solutions Inc
- Avicanna Inc
- Avidea Technologies Inc
- Avotres Inc
- Axxam SpA
- Barricade Therapeutics Corp
- Bayer AG
- Baylx Inc
- BioApex sro
- Bioasis Technologies Inc
- Biocad
- Biocon Ltd
- Biocure Technology Inc
- Biogen Inc
- BioIncept LLC
- Bionorica SE
- BioNTech SE
- BioSyngen Pte Ltd
- Biovista Inc
- BioXpress Therapeutics SA
- Bisichem Co Ltd
- Bolder Biotechnology Inc
- Boston Pharmaceuticals Inc
- BoYen Therapeutics Inc
- BrainStorm Cell Therapeutics Inc
- Bridge Biotherapeutics Inc
- Bristol-Myers Squibb Co
- BTB Pharma AB
- CarthroniX Inc
- CavoGene LifeSciences
- Cellerys AG
- Cellix Bio Pvt Ltd
- Cerion LLC
- CGeneTech (Suzhou China) Co Ltd
- Cinnagen Co
- Clene Inc
- Complement Pharma BV
- Compugen Ltd
- Convelo Therapeutics Inc
- Cresence AS
- CSPC Pharmaceutical Group Ltd
- CuraVac Inc
- CuroNZ Ltd
- Cytodyn Inc
- Cyxone AB
- DC4U BV
- Denali Therapeutics Inc
- DiNonA Inc
- Disarm Therapeutics Inc
- Dr. Reddy's Laboratories Ltd
- Dragonfly Therapeutics Inc
- Dualogics Corp
- EA Pharma Co Ltd
- Eikonoklastes Therapeutics Inc
- Eldrug SA
- Eli Lilly and Co
- ENCEFA
- Endece LLC
- Epitracker Inc
- Erganeo
- Ever Supreme Bio Technology Co Ltd
- Evgen Pharma Plc
- Evopoint Bioscience Co Ltd
- F. Hoffmann-La Roche Ltd
- f5 Therapeutics Inc
- Farmacija d.o.o. Tuzla
- FibroGenesis LLC
- Find Therapeutics Inc
- Fortuna Fix Inc
- Frequency Therapeutics Inc
- FSD Pharma Inc
- GABA Therapeutics Inc
- Galmed Pharmaceuticals Ltd
- Genentech USA Inc
- Generos Biomedical Technology (Hangzhou) Co Ltd
- Genervon Biopharmaceuticals LLC
- GeNeuro SA
- Gilead Sciences Inc
- Glialogix Inc
- Glixogen Therapeutics
- Gossamer Bio Inc
- GSK plc
- Guangzhou BeBetter Medicine Technology Co Ltd
- Guangzhou Lupeng Pharmaceutical Co Ltd
- H. Lundbeck AS
- Hope Biosciences LLC
- HuniLife Biotechnology Inc
- iCell Gene Therapeutics LLC
- Idorsia Pharmaceutical Ltd
- Iltoo Pharma
- ImCyse SA
- Immune Response BioPharma Inc
- Immungenetics AG
- Immunic Inc
- ImmunoBiome Inc
- ImmunoChem Therapeutics LLC
- Immunwork Inc
- ImmusanT Inc
- Immutep Ltd
- Impetis Biosciences Ltd
- Imstem Biotechnology Inc
- InFlectis BioScience SAS
- Inmagene Biopharmaceuticals Ltd
- Inmune Bio Inc
- InnoBioscience LLC
- InnoCare Pharma Ltd
- Innovimmune Biotherapeutics Inc
- Io Therapeutics Inc
- ISOThrive Inc
- Istesso Ltd
- J2H Biotech
- Johnson & Johnson
- JSR Life Sciences LLC
- Jura Bio Inc
- Jyant Technologies Inc
- Karo Pharma AB
- Klogene Therapeutics Inc
- Kogenix Therapeutics Inc
- Kymera Therapeutics Inc
- Kyorin Pharmaceutical Co Ltd
- Landos Biopharma Inc
- Lead Discovery Center GmbH
- Leukosight Inc
- LFB SA
- LIFNano Rx Ltd
- Lys Therapeutics SAS
- Mabion SA
- MAKScientific LLC
- Malachite Innovations Inc
- Mapi Pharma Ltd
- Maruho Co Ltd
- MD Healthcare Inc
- Med-Life Discoveries LP
- MedAnnex Ltd
- MedDay SA
- Medsenic SAS
- Mercaptor Discoveries Inc
- Merck & Co Inc
- Merck KGaA
- MetiMedi Pharmaceuticals Co Ltd
- MetrioPharm AG
- Millennium Pharmaceuticals Inc
- Mitochon Pharmaceuticals Inc
- Mitotech SA
- Mitsubishi Tanabe Pharma Corp
- MMJ International Holdings Corp
- Mochida Pharmaceutical Co Ltd
- Moderna Inc
- Molecules For Health Inc
- MorphoSys AG
- MyMD Pharmaceuticals Inc
- Nanjing Aimeifei Biomedical Technology Co Ltd
- NervGen Pharma Corp
- Neuraly Inc
- Neuren Pharmaceuticals Ltd
- Neuro Vigor LLC
- NeuroGenesis Ltd
- NeuroScientific Biopharmaceuticals Ltd
- New World Laboratories Inc
- Novartis AG
- Novellus Therapeutics Ltd
- Novoron Bioscience Inc
- Numab Therapeutics AG
- Oculis SA
- Omeros Corp
- Oncodesign SA
- Op-T-Mune Inc
- Orion Biotechnology Canada Ltd
- Orpheris Inc
- Oryzon Genomics SA
- OSE Immunotherapeutics SA
- Ossianix Inc
- Pahan Therapeutics
- Palisade Bio, Inc
- Pangen Biotech Inc
- Par'Immune SAS
- Parkside Scientific Inc
- Parvus Therapeutics Inc
- Pasithea Therapeutics Corp
- PB Immune Therapeutics Co Ltd
- PharmatrophiX Inc
- PharmCADD Co Ltd
- Pheno Therapeutics Ltd
- Pipeline Therapeutics Inc
- Polpharma Biologics SA
- PolTREG SA
- PrecisemAb Biotech Co Ltd
- Principia Biopharma Inc
- Progenitor Therapeutics Ltd
- ProNoxis AB
- Protheragen Inc
- Provid Pharmaceuticals Inc
- Q Therapeutics Inc
- Quimatryx SL
- ReceptoPharm Inc
- RegeneRx Biopharmaceuticals Inc
- Rekover Therapeutics Ltd
- RemeGen Co Ltd
- ReNetX Bio
- ReNeuroGen LLC
- Resverlogix Corp
- Revalesio Corp
- Reven Holdings Inc
- Rewind Therapeutics NV
- Rigel Pharmaceuticals Inc
- Riptide Bioscience Inc
- Sana Biotechnology Inc
- SanBio Co Ltd
- Sangamo Therapeutics Inc
- Sanofi
- Sansho Co Ltd
- Santhera Pharmaceuticals Holding AG
- Sarepta Therapeutics Inc
- Sareum Holdings Plc
- Scientus Pharma Inc
- Score Pharma Inc
- Senda Biosciences Inc
- Senzer Ltd
- Serenity Bioworks Inc
- Shanghai Pharmaceutical Group Co Ltd
- Shanxi Zhendong Pharmaceutical Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Silo Pharma Inc
- SinoCelltech Group Ltd
- Sironax Ltd
- Sorrento Therapeutics Inc
- Statera Biopharma Inc
- Stem Cell Medicine Ltd
- Sujana Biotech, LLC
- Suzhou Connect Biopharmaceuticals Ltd
- SynAct Pharma AB
- Synaptogenix Inc
- Takeda Pharmaceutical Co Ltd
- Tavanta Therapeutics Inc
- Teikoku Pharma USA Inc
- TeraImmune Inc
- Tetra Therapeutics
- Tevogen Bio Inc
- Theratome Bio Inc
- Therini Bio Inc
- Tiziana Life Sciences Plc
- TolerogenixX GmbH
- Tonix Pharmaceuticals Holding Corp
- Transparency Life Sciences LLC
- Travecta Therapeutics Pte Ltd
- Trio Medicines Ltd
- Twinpigbiolab Co Ltd
- TwotoBiotech Ltd
- UBI Pharma Inc
- UCB SA
- USA Elixiria Biotech Inc
- Vaccinex Inc
- Vascular Biogenics Ltd
- Vertex Pharmaceuticals Inc
- Vir Biotechnology Inc
- Virogenomics BioDevelopment Inc
- Virtici LLC
- Vitalis LLC
- Vitro Biopharma Inc
- Voronoi Group
- West Lake Biomedical Technology (Hangzhou) Co Ltd
- Worg Pharmaceuticals Hangzhou Co Ltd
- Xalud Therapeutics Inc
- Xonovo Inc
- XOStem Biosciences Ltd
- Zydus Lifesciences Ltd
- ZyVersa Therapeutics Inc
